Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ChloraPrep One-Step approval

This article was originally published in The Tan Sheet

Executive Summary

Topical antiseptic consisting of chlorhexidine gluconate 2% and isopropyl alcohol 70% for preparation of skin prior to injection approved by FDA Oct. 7. NDA 21-555 was submitted on behalf of Medi-Flex Hospital Products by its agent, Beckloff Associates. In July 2000, agency approved the formulation as an OTC pre-operative skin prep (1"The Tan Sheet" July 24, 2000, In Brief). In April, FDA gave the nod to supplemental NDA 20-832/SCS-002 to change the ampoule size and volume and incorporate labeling changes on the pre-op skin preparation...

You may also be interested in...



ChloraPrep One-Step NDA

FDA approves NDA for chlorhexidine gluconate 2% and isopropyl alcohol 70% preoperative skin preparation July 14. The OTC topical antiseptic is indicated for professional use, the agency notes in its letter to Overland Park, Kan.-based Medi-Flex Hospital Products, finding "adequate information has been presented to demonstrate that the drug product is safe and effective for use"

The Good, The Bad And The Ugly Of COVID-19 Vaccine Manufacturing Technology Platforms

Not all technology platforms provide the expected benefit of filling in CMC review gaps and speeding coronavirus vaccine approvals.

SparingVision Raises €44.5m For Mutation-Agnostic Eye Gene Therapy

A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel